

# Helena Santos

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7849520/publications.pdf>

Version: 2024-02-01

15  
papers

355  
citations

933447

10  
h-index

996975

15  
g-index

15  
all docs

15  
docs citations

15  
times ranked

549  
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparative effectiveness and predictors of response to tumour necrosis factor inhibitor therapies in rheumatoid arthritis. <i>Rheumatology</i> , 2012, 51, 2020-2026.	1.9	78
2	Whole blood transcriptional profiling in ankylosing spondylitis identifies novel candidate genes that might contribute to the inflammatory and tissue-destructive disease aspects. <i>Arthritis Research and Therapy</i> , 2011, 13, R57.	3.5	70
3	GO-DACT: a phase 3b randomised, double-blind, placebo-controlled trial of GOLimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 490-498.	0.9	41
4	Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration. <i>RMD Open</i> , 2020, 6, e001280.	3.8	33
5	DAS28, CDAI and SDAI cut-offs do not translate the same information: results from the Rheumatic Diseases Portuguese Register Reuma.pt. <i>Rheumatology</i> , 2015, 54, 286-291.	1.9	22
6	Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries. <i>Arthritis Care and Research</i> , 2022, 74, 1205-1218.	3.4	20
7	Effectiveness of switching between TNF inhibitors in patients with axial spondyloarthritis: is the reason to switch relevant?. <i>Arthritis Research and Therapy</i> , 2020, 22, 195.	3.5	19
8	<i>TRAF1/C5</i> but Not <i>PTPRC</i> Variants Are Potential Predictors of Rheumatoid Arthritis Response to Anti-Tumor Necrosis Factor Therapy. <i>BioMed Research International</i> , 2015, 2015, 1-9.	1.9	15
9	Real-world Longterm Effectiveness of Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis Patients from the Rheumatic Diseases Portuguese Register. <i>Journal of Rheumatology</i> , 2020, 47, 690-700.	2.0	15
10	Eligibility criteria for biologic disease-modifying antirheumatic drugs in axial spondyloarthritis: going beyond BASDAI. <i>RMD Open</i> , 2020, 6, e001145.	3.8	12
11	Spectrum of ankylosing spondylitis in Portugal. Development of BASDAI, BASFI, BASMI and mSASSS reference centile charts. <i>Clinical Rheumatology</i> , 2012, 31, 447-454.	2.2	10
12	Validation of Portuguese-translated computer touch-screen questionnaires in patients with rheumatoid arthritis and spondyloarthritis, compared with paper formats. <i>Rheumatology International</i> , 2015, 35, 2029-2035.	3.0	9
13	<i>ANKH</i> and Susceptibility to and Severity of Ankylosing Spondylitis. <i>Journal of Rheumatology</i> , 2012, 39, 131-134.	2.0	8
14	The GO-DACT protocol: a multicentre, randomized, double-blind, parallel-group study to compare the efficacy of golimumab in combination with methotrexate (MTX) versus MTX monotherapy. <i>Acta Reumatolgica Portuguesa</i> , 2018, 43, 80-92.	0.2	2
15	Portuguese recommendations for the use of biological therapies in patients with axial spondyloarthritis–December 2011 update. <i>Acta Reumatolgica Portuguesa</i> , 2012, 37, 40-7.	0.2	1